{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:30:12Z","timestamp":1793075412145,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012416","name":"Inova Health System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02953-8","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T16:40:20Z","timestamp":1710348020000},"page":"566-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Development of a routine bedside CYP2C19 genotype assessment program\u00a0for antiplatelet therapy guidance in a community hospital catheterization laboratory"],"prefix":"10.1007","volume":"57","clinical-trial-number":[{"clinical-trial-number":"nct03040622","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5461-568X","authenticated-orcid":false,"given":"Paul A.","family":"Gurbel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bliden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sherwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjaneh","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juzer Ali","family":"Asgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"2953_CR1","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.111.031195","volume":"125","author":"PA Gurbel","year":"2012","unstructured":"Gurbel PA, Tantry US (2012) Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 125:1276\u20131287","journal-title":"Circulation"},{"key":"2953_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","volume":"112","author":"JA Lee Cr, Luzum","year":"2022","unstructured":"Lee Cr, Luzum JA, Sangkuhl K et al (2022) Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther 112:959\u2013967","journal-title":"Clin Pharmacol Ther"},{"key":"2953_CR3","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet JP et al (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821\u20131830","journal-title":"JAMA"},{"key":"2953_CR4","doi-asserted-by":"publisher","first-page":"e009434","DOI":"10.1161\/CIRCINTERVENTIONS.120.009434","volume":"14","author":"DMF Claassens","year":"2021","unstructured":"Claassens DMF, Bergmeijer TO, Vos GJA et al (2021) Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 genotype: a popular genetics subanalysis. Circ Cardiovasc Interv 14:e009434","journal-title":"Circ Cardiovasc Interv"},{"key":"2953_CR5","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","volume":"376","author":"JL Mega","year":"2010","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L et al (2010) Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376:1312\u20131319","journal-title":"Lancet"},{"key":"2953_CR6","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L, James S, Storey RF et al (2010) PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376:1320\u20131328","journal-title":"Lancet"},{"key":"2953_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR, O\u2019Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849\u2013857","journal-title":"JAMA"},{"key":"2953_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/j.1875-9114.2012.01048","volume":"32","author":"ES Reese","year":"2012","unstructured":"Reese ES, Daniel C, Beitelshees AL, Onukwugha E (2012) Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 32:323\u2013332","journal-title":"Pharmacotherapy"},{"key":"2953_CR9","unstructured":"FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/Postmarket%20Drug%20Safety%20Information%20for%20Patients%20and%20Providers\/ucm203888.htm Drug Safety Information for Patients and"},{"key":"2953_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Clinical Pharmacogenetics Implementation Consortium et al (2013) Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94:317\u2013323","journal-title":"Clin Pharmacol Ther"},{"key":"2953_CR11","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","volume":"379","author":"JD Roberts","year":"2012","unstructured":"Roberts JD, Wells GA, Le May MR et al (2012) Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379:1705\u20131711","journal-title":"Lancet"},{"key":"2953_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/hrt.2011.227652","volume":"98","author":"M Zabalza","year":"2012","unstructured":"Zabalza M, Subirana I, Sala J, Lluis-Ganella C et al (2012) Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 98:100\u2013108","journal-title":"Heart"},{"key":"2953_CR13","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","volume":"381","author":"DMF Claassens","year":"2019","unstructured":"Claassens DMF, Vos GJA, Bergmeijer TO et al (2019) A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 381:1621\u20131631","journal-title":"N Engl J Med"},{"key":"2953_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.2020.12443","volume":"324","author":"NL Pereira","year":"2020","unstructured":"Pereira NL, Farkouh ME, So D et al (2020) Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA 324:761\u2013771","journal-title":"JAMA"},{"key":"2953_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","volume":"14","author":"NL Pereira","year":"2021","unstructured":"Pereira NL, Rihal C, Lennon R et al (2021) Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv 14:739\u2013750","journal-title":"JACC Cardiovasc Interv"},{"key":"2953_CR16","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","volume":"385","author":"Y Wang","year":"2021","unstructured":"Wang Y, Meng X, Wang A et al (2021) For the CHANCE-2 investigators. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med 385:2520\u20132530","journal-title":"N Engl J Med"},{"key":"2953_CR17","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","volume":"58","author":"GN Levine","year":"2011","unstructured":"Levine GN, Bates ER, Blankenship JC et al (2011) 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American college of cardiology foundation\/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol 58:e44-122","journal-title":"J Am Coll Cardiol"},{"key":"2953_CR18","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIRCULATIONAHA.121.057538","volume":"145","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S et al (2022) 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation 145:e18\u2013e114","journal-title":"Circulation"},{"key":"2953_CR19","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","volume":"12","author":"D Sibbing","year":"2019","unstructured":"Sibbing D, Aradi D, Alexopoulos D et al (2019) Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 12:1521\u20131537","journal-title":"JACC Cardiovasc Interv"},{"key":"2953_CR20","unstructured":"State v Bristol-Myers Squibb Company,\u00a0(2021) civil No. 14-1-0708-03 DEO. (Haw Cir Ct February 15)"},{"key":"2953_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12967-018-1469-8","volume":"16","author":"LH Cavallari","year":"2018","unstructured":"Cavallari LH, Franchi F, Rollini F et al (2018) Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Translational Med 16:92","journal-title":"J Translational Med"},{"key":"2953_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2217\/pgs-2018-0013","volume":"19","author":"TO Bergmeijer","year":"2019","unstructured":"Bergmeijer TO, Vos GJ, Claassens DMF et al (2019) Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy. Pharmacogenomics 19:621\u2013628","journal-title":"Pharmacogenomics"},{"key":"2953_CR23","unstructured":"Multi-partner grant awarded for the validation of Genedrive\u00ae CYP2C19 ID Kit in time critical NHS settings.\nhttp:\/\/www.genedriveplc.com\/press-releases\/gdr_-_devote_(16.06.23).pdf. Accessed 5 Jan 2024"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02953-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02953-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02953-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T08:09:00Z","timestamp":1713427740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02953-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2953"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02953-8","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"assertion":[{"value":"19 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Paul A Gurbel, Dr. Gurbel has received consulting fees and\/or honoraria from Bayer, Vectura\/Otitopic, Janssen, Cleveland Clinic foundation, Wolters Kluwer Pharma, Web MD Medscape, Baron and Budd, Premier Health Care Resource, Baim Institute, and Medforce; institutional research grants from Accriva Diagnostics, AstraZeneca, Bayer, Cronos, Janssen Pharmaceuticals Inc., Haemonetics, Hikari Dx, Idorisa, Labcorp Drug Development, Novartis, Prolocor, Recor Medical, Vectura Limited, Zoll Medical Corporation; in addition, Dr. Gurbel has two patents, Detection of restenosis risk in patients issued and Assessment of cardiac health and thrombotic risk in a patient. Dr. Gurbel was an expert witness in a lawsuit associated with Plavix. Other authors report no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}